Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insilico Medicine
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Deal Snapshot: Following its diabetes deal with Biolojic by four months, Lilly’s partnership with Verge on using AI to discover ALS drugs is just the latest of numerous tech-biopharma tie-ups.
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
Building a robotics infrastructure "is the only way to make sure we generate data of sufficient quality at the speed and scale required, and now everybody in the pharma industry is very excited about the idea of end-to-end automation." So says Martin-Immanuel Bittner, CEO of .
- Digital Health
- Drug Discovery Tools